Camurus Strengthens Executive Team With New Corporate Development Chief

Camurus AB ( (SE:CAMX) ) has issued an update.

Camurus, a biopharmaceutical company specializing in long-acting treatments for severe and chronic conditions, develops new drug products based on its proprietary FluidCrystal technology and maintains a diversified pipeline in dependence, pain, cancer, and endocrine diseases. Headquartered in Lund, Sweden, the company operates across Europe, the US, and Australia and is listed on Nasdaq Stockholm under the ticker CAMX.

Camurus has appointed industry veteran Jane Buus Laursen as Chief Corporate Development Officer and member of the executive management team, effective 23 March 2026, bringing more than two decades of business and corporate development experience from Novo Nordisk and AstraZeneca. The new role positions her to drive strategic development, licensing, M&A, and long-term growth initiatives at a time of ongoing expansion for Camurus, underlining the company’s focus on scaling its global footprint and enhancing shareholder value.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK760.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.

More about Camurus AB

Camurus is an international, science-led biopharmaceutical company focused on developing and commercializing innovative long-acting medicines for severe and chronic diseases. Leveraging its proprietary FluidCrystal technology and in-house R&D, the company is advancing a pipeline targeting dependence, pain, cancer, and endocrine disorders, with operations in Europe, the US, and Australia and a listing on Nasdaq Stockholm.

Average Trading Volume: 138,257

Technical Sentiment Signal: Sell

Current Market Cap: SEK33.14B

See more data about CAMX stock on TipRanks’ Stock Analysis page.